{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:12:55Z","timestamp":1776867175565,"version":"3.51.2"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100011912","name":"WUSTL | Washington University School of Medicine in St. Louis","doi-asserted-by":"publisher","award":["Faculty Diversity Scholar Awa"],"award-info":[{"award-number":["Faculty Diversity Scholar Awa"]}],"id":[{"id":"10.13039\/100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003085","name":"Longer Life Foundation","doi-asserted-by":"publisher","award":["No award number"],"award-info":[{"award-number":["No award number"]}],"id":[{"id":"10.13039\/100003085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","award":["No award number"],"award-info":[{"award-number":["No award number"]}],"id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"DOI":"10.1038\/s41389-025-00579-w","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:58:41Z","timestamp":1759755521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Investigation of lncRNA expression in newly diagnosed multiple myeloma reveals a LINC01432-CELF2 axis as an inhibitor of apoptosis"],"prefix":"10.1038","volume":"14","author":[{"given":"Richa","family":"Mishra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasanth","family":"Thunuguntla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhanusha","family":"Duraiyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alani","family":"Perkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7857-9442","authenticated-orcid":false,"given":"Katelyn","family":"Bagwill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8519-7671","authenticated-orcid":false,"given":"Savannah","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7431-2222","authenticated-orcid":false,"given":"Catheryn","family":"Sizemore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Brizuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaiyana","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8185-3142","authenticated-orcid":false,"given":"Stephen","family":"Daly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Jae","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdote","family":"Abebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yash","family":"Rajana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christ","family":"Enyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruthi","family":"Rangineni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Fortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2368-4890","authenticated-orcid":false,"given":"Reyka","family":"Jayasinghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1517-2975","authenticated-orcid":false,"given":"Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"DiPersio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8146-9331","authenticated-orcid":false,"given":"Jessica","family":"Silva-Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"579_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"579_CR2","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1586\/14737140.7.7.945","volume":"7","author":"P Falco","year":"2007","unstructured":"Falco P, Bringhen S, Avonto I, Gay F, Morabito F, Boccadoro M, et al. Melphalan and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther. 2007;7:945\u201357.","journal-title":"Expert Rev Anticancer Ther"},{"key":"579_CR3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1517\/13543784.2013.788643","volume":"22","author":"M Martino","year":"2013","unstructured":"Martino M, Olivieri A, Offidani M, Vigna E, Moscato T, Fedele R, et al. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. Expert Opin Investig Drugs. 2013;22:619\u201334.","journal-title":"Expert Opin Investig Drugs"},{"key":"579_CR4","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.1995.13.7.1786","volume":"13","author":"BL Samuels","year":"1995","unstructured":"Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol. 1995;13:1786\u201399.","journal-title":"J Clin Oncol"},{"key":"579_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13:117.","journal-title":"Blood Cancer J"},{"key":"579_CR6","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41556-021-00766-y","volume":"23","author":"J Frede","year":"2021","unstructured":"Frede J, Anand P, Sotudeh N, Pinto RA, Nair MS, Stuart H, et al. Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. Nat Cell Biol. 2021;23:1199\u2013211.","journal-title":"Nat Cell Biol"},{"key":"579_CR7","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1172\/JCI129205","volume":"130","author":"SA Minnie","year":"2020","unstructured":"Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest. 2020;130:1565\u201375.","journal-title":"J Clin Invest"},{"key":"579_CR8","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.3390\/cancers13081976","volume":"13","author":"A Carrasco-Leon","year":"2021","unstructured":"Carrasco-Leon A, Amundarain A, Gomez-Echarte N, Prosper F, Agirre X. The role of lncRNAs in the pathobiology and clinical behavior of multiple myeloma. Cancers. 2021;13:1976.","journal-title":"Cancers"},{"key":"579_CR9","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.3390\/cancers14102348","volume":"14","author":"IF Coira","year":"2022","unstructured":"Coira IF, Rincon R, Cuendet M. The multiple myeloma landscape: epigenetics and non-coding RNAs. Cancers. 2022;14:2348.","journal-title":"Cancers"},{"key":"579_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00412-2","volume":"8","author":"AM Eteleeb","year":"2022","unstructured":"Eteleeb AM, Thunuguntla PK, Gelev KZ, Tang CY, Rozycki EB, Miller A, et al. LINC00355 regulates p27(KIP) expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer. NPJ Breast Cancer. 2022;8:49.","journal-title":"NPJ Breast Cancer"},{"key":"579_CR11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2217\/bmm-2022-0349","volume":"16","author":"S Leng","year":"2022","unstructured":"Leng S, Qu H, Lv X, Liu X. Role of ncRNA in multiple myeloma. Biomark Med. 2022;16:1181\u201391.","journal-title":"Biomark Med"},{"key":"579_CR12","doi-asserted-by":"crossref","unstructured":"Saltarella I, Apollonio B, Lamanuzzi A, Desantis V, Mariggio MA, Desaphy JF et al. The landscape of lncRNAs in multiple myeloma: implications in the \u201cHallmarks of Cancer\u201d, clinical perspectives and therapeutic opportunities. Cancers 2022;14:1963.","DOI":"10.3390\/cancers14081963"},{"key":"579_CR13","unstructured":"Silva J, Smith D. Long non-coding RNAs and Cancer. La Jolla, California: Caister Academic Press; 2012."},{"key":"579_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.4161\/rna.8.3.14800","volume":"8","author":"JM Silva","year":"2011","unstructured":"Silva JM, Boczek NJ, Berres MW, Ma X, Smith DI. LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation. RNA Biol. 2011;8:496\u2013505.","journal-title":"RNA Biol"},{"key":"579_CR15","doi-asserted-by":"crossref","unstructured":"Yang C, Liang Y, Shu J, Wang S, Hong Y, Chen K et al. Long non\u2011coding RNAs in multiple myeloma (Review). Int J Oncol. 2023:62:69.","DOI":"10.3892\/ijo.2023.5517"},{"key":"579_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11084-x","volume":"23","author":"Y Ren","year":"2023","unstructured":"Ren Y, Liu Y, He W, Zhao W, Pan J, Gao H, et al. Expression of NEAT1 can be used as a predictor for Dex resistance in multiple myeloma patients. BMC Cancer. 2023;23:630.","journal-title":"BMC Cancer"},{"key":"579_CR17","doi-asserted-by":"publisher","first-page":"6502","DOI":"10.7150\/jca.35098","volume":"10","author":"X Shen","year":"2019","unstructured":"Shen X, Shen P, Yang Q, Yin Q, Wang F, Cong H, et al. Knockdown of long non-coding RNA PCAT-1 inhibits myeloma cell growth and drug resistance via p38 and JNK MAPK pathways. J Cancer. 2019;10:6502\u201310.","journal-title":"J Cancer"},{"key":"579_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.14715\/cmb\/2020.66.6.14","volume":"66","author":"Y Wang","year":"2020","unstructured":"Wang Y, Xu S, Wang L, Liu J, Wang J, Zhou J. Long noncoding RNA H19 promotes vincristine resistance in multiple myeloma by targeting Akt. Cell Mol Biol. 2020;66:76\u201380.","journal-title":"Cell Mol Biol"},{"key":"579_CR19","doi-asserted-by":"publisher","first-page":"788","DOI":"10.4149\/neo_2021_210205N184","volume":"68","author":"LH Yang","year":"2021","unstructured":"Yang LH, Du P, Liu W, An LK, Li J, Zhu WY, et al. LncRNA ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN. Neoplasma. 2021;68:788\u201397.","journal-title":"Neoplasma"},{"key":"579_CR20","doi-asserted-by":"publisher","first-page":"106967","DOI":"10.1016\/j.leukres.2022.106967","volume":"123","author":"X Zang","year":"2022","unstructured":"Zang X, Wang J, Xia Y, Li J, Chen L, Gu Y, et al. LncRNA MEG3 promotes the sensitivity of bortezomib by inhibiting autophagy in multiple myeloma. Leuk Res. 2022;123:106967.","journal-title":"Leuk Res"},{"key":"579_CR21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","volume":"22","author":"L Statello","year":"2021","unstructured":"Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22:96\u2013118.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"579_CR22","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/path.5405","volume":"250","author":"I Tsagakis","year":"2020","unstructured":"Tsagakis I, Douka K, Birds I, Aspden JL. Long non-coding RNAs in development and disease: conservation to mechanisms. J Pathol. 2020;250:480\u201395.","journal-title":"J Pathol"},{"key":"579_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.molmed.2018.01.001","volume":"24","author":"G Arun","year":"2018","unstructured":"Arun G, Diermeier SD, Spector DL. Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med. 2018;24:257\u201377.","journal-title":"Trends Mol Med"},{"key":"579_CR24","doi-asserted-by":"publisher","first-page":"13242","DOI":"10.1002\/anie.201808823","volume":"57","author":"A Donlic","year":"2018","unstructured":"Donlic A, Morgan BS, Xu JL, Liu A, Roble C Jr., Hargrove AE. Discovery of small molecule ligands for MALAT1 by tuning an RNA-binding scaffold. Angew Chem Int Ed Engl. 2018;57:13242\u20137.","journal-title":"Angew Chem Int Ed Engl"},{"key":"579_CR25","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2174\/1389450123666220919122520","volume":"23","author":"A Sangeeth","year":"2022","unstructured":"Sangeeth A, Malleswarapu M, Mishra A, Gutti RK. Long non-coding RNA therapeutics: recent advances and challenges. Curr Drug Targets. 2022;23:1457\u201364.","journal-title":"Curr Drug Targets"},{"key":"579_CR26","doi-asserted-by":"publisher","first-page":"aah7111","DOI":"10.1126\/science.aah7111","volume":"355","author":"SJ Liu","year":"2017","unstructured":"Liu SJ, Horlbeck MA, Cho SW, Birk HS, Malatesta M, He D, et al. CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. Science. 2017;355:aah7111.","journal-title":"Science"},{"key":"579_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1001091","volume":"9","author":"DM Church","year":"2011","unstructured":"Church DM, Schneider VA, Graves T, Auger K, Cunningham F, Bouk N, et al. Modernizing reference genome assemblies. PLoS Biol. 2011;9:e1001091.","journal-title":"PLoS Biol"},{"key":"579_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2003-4-5-p3","volume":"4","author":"G Dennis Jr.","year":"2003","unstructured":"Dennis G Jr., Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4:P3.","journal-title":"Genome Biol"},{"key":"579_CR29","doi-asserted-by":"publisher","first-page":"D287","DOI":"10.1093\/nar\/gkab702","volume":"50","author":"W Zhao","year":"2022","unstructured":"Zhao W, Zhang S, Zhu Y, Xi X, Bao P, Ma Z, et al. POSTAR3: an updated platform for exploring post-transcriptional regulation coordinated by RNA-binding proteins. Nucleic Acids Res. 2022;50:D287\u2013D294.","journal-title":"Nucleic Acids Res"},{"key":"579_CR30","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41588-023-01357-3","volume":"55","author":"SV Puram","year":"2023","unstructured":"Puram SV, Mints M, Pal A, Qi Z, Reeb A, Gelev K, et al. Cellular states are coupled to genomic and viral heterogeneity in HPV-related oropharyngeal carcinoma. Nat Genet. 2023;55:640\u201350.","journal-title":"Nat Genet"},{"key":"579_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-1-4939-8766-5_3","volume":"1861","author":"C Chu","year":"2018","unstructured":"Chu C, Chang HY. ChIRP-MS: RNA-Directed Proteomic Discovery. Methods Mol Biol. 2018;1861:37\u201345.","journal-title":"Methods Mol Biol"},{"key":"579_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15547-8","volume":"11","author":"JM Silva-Fisher","year":"2020","unstructured":"Silva-Fisher JM, Dang HX, White NM, Strand MS, Krasnick BA, Rozycki EB, et al. Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. Nat Commun. 2020;11:2156.","journal-title":"Nat Commun"},{"key":"579_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000492846","volume":"49","author":"X Shen","year":"2018","unstructured":"Shen X, Bai H, Zhu H, Yan Q, Yang Y, Yu W, et al. Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate HOXA11 expression by sponging miR-181a in multiple myeloma. Cell Physiol Biochem 2018;49:87\u2013100.","journal-title":"Cell Physiol Biochem"},{"key":"579_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.cca.2018.02.019","volume":"480","author":"Y Pan","year":"2018","unstructured":"Pan Y, Chen H, Shen X, Wang X, Ju S, Lu M, et al. Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma. Clin Chim Acta. 2018;480:199\u2013205.","journal-title":"Clin Chim Acta"},{"key":"579_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18056-9","volume":"7","author":"Y Sun","year":"2017","unstructured":"Sun Y, Pan J, Zhang N, Wei W, Yu S, Ai L. Knockdown of long non-coding RNA H19 inhibits multiple myeloma cell growth via NF-kappaB pathway. Sci Rep. 2017;7:18079.","journal-title":"Sci Rep"},{"key":"579_CR36","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/jmedgenet-2018-105437","volume":"55","author":"I Galvan-Femenia","year":"2018","unstructured":"Galvan-Femenia I, Obon-Santacana M, Pineyro D, Guindo-Martinez M, Duran X, Carreras A, et al. Multitrait genome association analysis identifies new susceptibility genes for human anthropometric variation in the GCAT cohort. J Med Genet. 2018;55:765\u201378.","journal-title":"J Med Genet"},{"key":"579_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharm Toxicol. 2010;50:259\u201393.","journal-title":"Annu Rev Pharm Toxicol"},{"key":"579_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/nat.2016.0656","volume":"27","author":"ST Crooke","year":"2017","unstructured":"Crooke ST. Molecular mechanisms of antisense oligonucleotides. Nucleic Acid Therapeutics. 2017;27:70\u201377.","journal-title":"Nucleic Acid Therapeutics"},{"key":"579_CR39","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.3390\/jcm9062004","volume":"9","author":"K Dhuri","year":"2020","unstructured":"Dhuri K, Bechtold C, Quijano E, Pham H, Gupta A, Vikram A, et al. Antisense oligonucleotides: an emerging area in drug discovery and development. J Clin Med. 2020;9:2004.","journal-title":"J Clin Med"},{"key":"579_CR40","doi-asserted-by":"publisher","first-page":"963689720986080","DOI":"10.1177\/0963689720986080","volume":"30","author":"C Li","year":"2021","unstructured":"Li C, Mu J, Shi Y, Xin H. LncRNA CCDC26 interacts with CELF2 protein to enhance myeloid leukemia cell proliferation and invasion via the circRNA_ANKIB1\/miR-195-5p\/PRR11 Axis. Cell Transpl. 2021;30:963689720986080.","journal-title":"Cell Transpl"},{"key":"579_CR41","doi-asserted-by":"publisher","first-page":"11056","DOI":"10.3390\/ijms222011056","volume":"22","author":"M Nasiri-Aghdam","year":"2021","unstructured":"Nasiri-Aghdam M, Garcia-Garduno TC, Jave-Suarez LF. CELF Family proteins in cancer: highlights on the RNA-binding protein\/noncoding RNA regulatory axis. Int J Mol Sci. 2021;22:11056.","journal-title":"Int J Mol Sci"},{"key":"579_CR42","doi-asserted-by":"crossref","unstructured":"Shi M, Yang R, Lin J, Wei QI, Chen L, Gong W et al. (2021). LncRNA-SNHG16 promotes proliferation and migration of acute myeloid leukemia cells via PTEN\/PI3K\/AKT axis through suppressing CELF2 protein. J Biosci. 2021;46:4.","DOI":"10.1007\/s12038-020-00127-1"},{"key":"579_CR43","doi-asserted-by":"publisher","first-page":"7559","DOI":"10.1111\/jcmm.16791","volume":"25","author":"L Wang","year":"2021","unstructured":"Wang L, Liu Z, Liu L, Guo C, Jiao D, Li L, et al. CELF2 is a candidate prognostic and immunotherapy biomarker in triple-negative breast cancer and lung squamous cell carcinoma: a pan-cancer analysis. J Cell Mol Med. 2021;25:7559\u201374.","journal-title":"J Cell Mol Med"},{"key":"579_CR44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/carcin\/bgz113","volume":"41","author":"YT Yeung","year":"2020","unstructured":"Yeung YT, Fan S, Lu B, Yin S, Yang S, Nie W, et al. CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction. Carcinogenesis. 2020;41:377\u201389.","journal-title":"Carcinogenesis"},{"key":"579_CR45","doi-asserted-by":"publisher","first-page":"104671","DOI":"10.1016\/j.yexmp.2021.104671","volume":"122","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Zhou H, Dong W. LncRNA RHPN1-AS1 promotes the progression of nasopharyngeal carcinoma by targeting CELF2 expression. Exp Mol Pathol. 2021;122:104671.","journal-title":"Exp Mol Pathol"},{"key":"579_CR46","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/s41375-022-01559-4","volume":"36","author":"J O\u2019Neal","year":"2022","unstructured":"O\u2019Neal J, Ritchey JK, Cooper ML, Niswonger J, Sofia Gonzalez L, Street E, et al. CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells. Leukemia. 2022;36:1625\u201334.","journal-title":"Leukemia"},{"key":"579_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14619-z","volume":"11","author":"SV Radhakrishnan","year":"2020","unstructured":"Radhakrishnan SV, Luetkens T, Scherer SD, Davis P, Vander Mause ER, Olson ML, et al. CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nat Commun. 2020;11:798.","journal-title":"Nat Commun"},{"key":"579_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add7900","volume":"15","author":"ER Vander Mause","year":"2023","unstructured":"Vander Mause ER, Baker JM, Dietze KA, Radhakrishnan SV, Iraguha T, Omili D, et al. Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity. Sci Transl Med. 2023;15:eadd7900.","journal-title":"Sci Transl Med"},{"key":"579_CR49","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1080\/10428194.2017.1295144","volume":"58","author":"G Bernardini","year":"2017","unstructured":"Bernardini G, Vulpis E, Bonanni V, Stabile H, Ricciardi MR, Petrucci MT, et al. High expression levels of IP10\/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma. Leuk Lymphoma. 2017;58:2493\u20136.","journal-title":"Leuk Lymphoma"},{"key":"579_CR50","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.3109\/10428194.2016.1151511","volume":"57","author":"A Bolomsky","year":"2016","unstructured":"Bolomsky A, Schreder M, Hubl W, Zojer N, Hilbe W, Ludwig H. Monokine induced by interferon gamma (MIG\/CXCL9) is an independent prognostic factor in newly diagnosed myeloma. Leuk Lymphoma. 2016;57:2516\u201325.","journal-title":"Leuk Lymphoma"},{"key":"579_CR51","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10495-018-1482-7","volume":"23","author":"P Wang","year":"2018","unstructured":"Wang P, Peng X, Zhang J, Wang Z, Meng J, Cen B, et al. LncRNA-135528 inhibits tumor progression by up-regulating CXCL10 through the JAK\/STAT pathway. Apoptosis. 2018;23:651\u201366.","journal-title":"Apoptosis"},{"key":"579_CR52","doi-asserted-by":"publisher","first-page":"811122","DOI":"10.3389\/fimmu.2022.811122","volume":"13","author":"X Ji","year":"2022","unstructured":"Ji X, Meng W, Liu Z, Mu X. Emerging roles of lncRNAs regulating RNA-mediated type-I interferon signaling pathway. Front Immunol. 2022;13:811122.","journal-title":"Front Immunol"},{"key":"579_CR53","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3892\/ol.2011.300","volume":"2","author":"M Liu","year":"2011","unstructured":"Liu M, Guo S, Stiles JK. The emerging role of CXCL10 in cancer (Review). Oncol Lett. 2011;2:583\u20139.","journal-title":"Oncol Lett"},{"key":"579_CR54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.virusres.2015.09.023","volume":"212","author":"S Valadkhan","year":"2016","unstructured":"Valadkhan S, Gunawardane LS. lncRNA-mediated regulation of the interferon response. Virus Res. 2016;212:127\u201336.","journal-title":"Virus Res"},{"key":"579_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-023-02993-z","volume":"21","author":"H Tuo","year":"2023","unstructured":"Tuo H, Liu R, Wang Y, Yang W, Liu Q. Hypoxia-induced lncRNA MRVI1-AS1 accelerates hepatocellular carcinoma progression by recruiting RNA-binding protein CELF2 to stabilize SKA1 mRNA. World J Surg Oncol. 2023;21:111.","journal-title":"World J Surg Oncol"},{"key":"579_CR56","first-page":"67","volume":"33","author":"Y Yang","year":"2022","unstructured":"Yang Y, Cheng Y, Mou Y, Tang X, Mu X. Natural antisense long noncoding RNA HHIP-AS1 suppresses non-small-cell lung cancer progression by increasing HHIP stability via interaction with CELF2. Crit Rev Eukaryot Gene Expr. 2022;33:67\u201377.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"579_CR57","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/15476286.2016.1176663","volume":"13","author":"S Ajith","year":"2016","unstructured":"Ajith S, Gazzara MR, Cole BS, Shankarling G, Martinez NM, Mallory MJ, et al. Position-dependent activity of CELF2 in the regulation of splicing and implications for signal-responsive regulation in T cells. RNA Biol. 2016;13:569\u201381.","journal-title":"RNA Biol"},{"key":"579_CR58","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1016\/j.celrep.2019.08.022","volume":"28","author":"R Chatrikhi","year":"2019","unstructured":"Chatrikhi R, Mallory MJ, Gazzara MR, Agosto LM, Zhu WS, Litterman AJ, et al. RNA binding protein CELF2 regulates signal-induced alternative polyadenylation by competing with enhancers of the polyadenylation machinery. Cell Rep. 2019;28:2795\u2013806 e2793.","journal-title":"Cell Rep"},{"key":"579_CR59","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1093\/nar\/gkaa295","volume":"48","author":"MJ Mallory","year":"2020","unstructured":"Mallory MJ, McClory SP, Chatrikhi R, Gazzara MR, Ontiveros RJ, Lynch KW. Reciprocal regulation of hnRNP C and CELF2 through translation and transcription tunes splicing activity in T cells. Nucleic Acids Res. 2020;48:5710\u20139.","journal-title":"Nucleic Acids Res"},{"key":"579_CR60","doi-asserted-by":"publisher","first-page":"130299","DOI":"10.1016\/j.bbagen.2022.130299","volume":"1867","author":"L Bao","year":"2023","unstructured":"Bao L, Wang Y, Lu M, Shi L, Chu B, Gao S. BDNF\/TrkB confers bortezomib resistance in multiple myeloma by inducing BRINP3. Biochim Biophys Acta Gen Subj. 2023;1867:130299.","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"579_CR61","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1089\/dna.2019.5196","volume":"39","author":"A Li","year":"2020","unstructured":"Li A, Li X, Chen X, Zeng C, Wang Z, Li Z, et al. NUPR1 silencing induces autophagy-mediated apoptosis in multiple myeloma cells through the PI3K\/AKT\/mTOR pathway. DNA Cell Biol. 2020;39:368\u201378.","journal-title":"DNA Cell Biol"},{"key":"579_CR62","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood-2014-12-618595","volume":"126","author":"M Lu","year":"2015","unstructured":"Lu M, Xia L, Liu YC, Hochman T, Bizzari L, Aruch D, et al. Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. Blood. 2015;126:972\u201382.","journal-title":"Blood"},{"key":"579_CR63","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1182\/blood-2004-08-3096","volume":"105","author":"RN Pearse","year":"2005","unstructured":"Pearse RN, Swendeman SL, Li Y, Rafii D, Hempstead BL. A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood. 2005;105:4429\u201336.","journal-title":"Blood"},{"key":"579_CR64","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s42003-022-03705-1","volume":"5","author":"P Santofimia-Castano","year":"2022","unstructured":"Santofimia-Castano P, Huang C, Liu X, Xia Y, Audebert S, Camoin L, et al. NUPR1 protects against hyperPARylation-dependent cell death. Commun Biol. 2022;5:732.","journal-title":"Commun Biol"},{"key":"579_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-021-08211-y","volume":"22","author":"D Wu","year":"2021","unstructured":"Wu D, Wang X, Han Y, Wang Y. The effect of lipocalin-2 (LCN2) on apoptosis: a proteomics analysis study in an LCN2 deficient mouse model. BMC Genom. 2021;22:892.","journal-title":"BMC Genom"},{"key":"579_CR66","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/genes12050614","volume":"12","author":"X Chen","year":"2021","unstructured":"Chen X, Sun Z. Novel lincRNA discovery and tissue-specific gene expression across 30 normal human tissues. Genes. 2021;12:614.","journal-title":"Genes"},{"key":"579_CR67","doi-asserted-by":"publisher","first-page":"7120","DOI":"10.18632\/oncotarget.6859","volume":"7","author":"C Jiang","year":"2016","unstructured":"Jiang C, Li Y, Zhao Z, Lu J, Chen H, Ding N, et al. Identifying and functionally characterizing tissue-specific and ubiquitously expressed human lncRNAs. Oncotarget. 2016;7:7120\u201333.","journal-title":"Oncotarget"},{"key":"579_CR68","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/978-1-0716-0771-8_3","volume":"2176","author":"R Maruyama","year":"2020","unstructured":"Maruyama R, Yokota T. Knocking down long noncoding RNAs using antisense oligonucleotide gapmers. Methods Mol Biol. 2020;2176:49\u201356.","journal-title":"Methods Mol Biol"},{"key":"579_CR69","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-1-4939-3378-5_16","volume":"1402","author":"T Zhou","year":"2016","unstructured":"Zhou T, Kim Y, MacLeod AR. Targeting long noncoding RNA with antisense oligonucleotide technology as cancer therapeutics. Methods Mol Biol. 2016;1402:199\u2013213.","journal-title":"Methods Mol Biol"},{"key":"579_CR70","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1182\/blood.2023021991","volume":"144","author":"K Grillone","year":"2024","unstructured":"Grillone K, Ascrizzi S, Cremaschi P, Amato J, Polera N, Croci O, et al. An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma. Blood. 2024;144:1705\u201321.","journal-title":"Blood"},{"key":"579_CR71","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1182\/blood.2022016892","volume":"141","author":"E Morelli","year":"2023","unstructured":"Morelli E, Fulciniti M, Samur MK, Ribeiro CF, Wert-Lamas L, Henninger JE, et al. A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth. Blood. 2023;141:391\u2013405.","journal-title":"Blood"},{"key":"579_CR72","doi-asserted-by":"crossref","unstructured":"Morelli E, Aktas Samur A, Maisano D, Gao C, Favasuli VK, Papaioannou D et al. CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs. Blood. 2025;146:847\u201360.","DOI":"10.1182\/blood.2025028746"},{"key":"579_CR73","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/nbt.3715","volume":"34","author":"S Zhu","year":"2016","unstructured":"Zhu S, Li W, Liu J, Chen CH, Liao Q, Xu P, et al. Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. Nat Biotechnol. 2016;34:1279\u201386.","journal-title":"Nat Biotechnol"}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-025-00579-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-025-00579-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-025-00579-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:04:59Z","timestamp":1759759499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-025-00579-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["579"],"URL":"https:\/\/doi.org\/10.1038\/s41389-025-00579-w","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MS (Consulting for DSMB and endpoint adjudication work: Sorrento, Marker Therapeutics, GSK, Kura Oncology, and NovoNordisk; Research support: Incyte, Janssen, Takeda, Ichnos Biosciences, Fate Therapeutics, and Karyopharm), RV (Consulting: BMS, Sanofi, Janssen, Karyopharm, Pfizer, Regenron; Research: BMS, Sanofi, Takeda), and JD (Consulting: Rivervest, Bluebird Bio, Vertex, HcBiosciences, SPARC; Equity-ownership WUGEN and Magenta; Research support: Macrogenics, Bioline, Incyte).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with relevant guidelines and regulations. This study was conducted under the supervision of the Washington University Human Rights Protections Office and in compliance with all relevant guidelines and regulations for clinical research. All participants in CoMMpass (NCT01454297) provided informed consent for that study. Only de-identified patient-level data was accessed for these analyses and, therefore, were determined to be exempt. NDMM patient bone marrow aspirates were obtained from the participants following informed consent and registration on our internal Multiple Myeloma Tissue Banking Protocol (protocol number 201102270). All animal experiment protocols in this study were reviewed and approved by the Institutional Animal Care and Use Committee of WashU (Protocol 24-0155).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"36"}}